Comparative study on three chemotherapeutic regimens for the treatment of advanced epithelial ovarian cancer

Abstract

To investigate the best first-line chemotherapy regimen for the treatment of advanced epithelial ovarian cancer (AEOC), the efficacy of three chemotherapy regimens for treatment of the patients with AEOC in our hospital during Jan. 1992- Jan. 1999 was retrospectively analyzed. The therapeutic effects were compared with the supplement of Melphalan + Hexamethylme (PAM + HMM), cisplatin+ adriamycin+cyclophosphamide or isofamide (PAC) or cisplatin+cyclophosphamide or isofamide (PC), Taxol+cisplatin (TP) combined chemotherapy after cytoreductive surgery. The results showed that the overall effective rate of TP was significantly higher than that of PAM + HMM (P < 0. 05); The complete remission rate of TP was significantly higher than that of PAM + HMM and PAC or PC (allP < 0. 05); The 2-year survival rate free of tumor of TP was obviously higher than that of PAM + HMM and PAC or PC(allP < 0. 05). It was concluded that the therapeutic effect of TP regimen in the treatment of AEOC was better than PAM + HMM and PAC or PC and TP regimen could be recommended currently as the preferred first-line one for the treatment of AEOC.

Keywords

epithelial ovarian cancer / combined chemotherapy / platinum / taxol

References

[1] 1998,33(12):749

[2] OmuraG, BlessingJ A, EhrlichcE, et al.. A randomized trial of cyclophosphamide and doxorubicin with or without cisplan in advanced ovarian carcinoma. Cancer, 1987, 56: 1725-1725

[3] DisaiaP H, CresamanW T. Clinical Gynecologic Oncology, 19975ndMissouriMissouri Mosby-Year Book, Inc.253-281

[4] 1994, 21: 216

[5] McGuireW P, HoskinsW J, BradyM F, et al.. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med, 1996, 334: 1-1

[6] McGuireW P, HoskinsW J, BradyM F, et al.. Taxol and cisplatin (TP) improves outcome in advanced ovarian cancer (AOC) as compared to cytoxan and cisplatin (CP). Proc ASCO, 1995, 14: 275-275

[7] OzolsR F. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Semin Oncol, 1999, 26(1): 84-84